Status:
COMPLETED
Erinacine A-enriched Hericium Erinaceus Mycelia for Improvement of Recognition, Vision, and Functional MRI Alterations
Lead Sponsor:
Chung Shan Medical University
Collaborating Sponsors:
Grape King Bio Ltd.
Conditions:
Supplement
Cognition Disorders in Old Age
Eligibility:
All Genders
50-90 years
Phase:
NA
Brief Summary
This study was designed as randomized double blind placebo study to investigate the efficacy of Erinacine A-enriched Hericium erinaceus mycelia for improvement of recognition, vision, and functional M...
Detailed Description
Patients were recruited with diagnosis of mild or medium dementia, according to criteria by NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease ...
Eligibility Criteria
Inclusion
- Aged between 50 and 90
- Confirmed diagnosis of mild and intermediate Alzheimer's disease based on clinical assessments according to criteria of NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association)
Exclusion
- vulnerable to injuries
- loss of self-recognition,
- loss of behavioral capacity
- with critical illness
- with major diseases
Key Trial Info
Start Date :
May 22 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 10 2017
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04065061
Start Date
May 22 2015
End Date
May 10 2017
Last Update
August 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung Shan Medical University Hospital
Taichung, Taiwan, 40201